Half a year after being spurned by the FDA and following deep layoffs, IO Biotech has decided to close its doors for good.

Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick ...

Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while ...

Shares of Oric Pharmaceuticals sank 40% Wednesday after the cancer biotech reported study results that were positive--but not positive enough for Wall Street. In an early-stage trial, Oric’s prostate- ...

The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.

Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech’s New York Reference Laboratory DUBLIN and NEW YORK, ...

Merck has struck a $5.7bn deal to buy Terns Pharmaceuticals, a US biotech developing treatments for a rare form of blood and ...

The FDA has warned a biotech company about claims that its bladder cancer drug could treat and prevent multiple types of cancer.

Federal health officials posted a warning about misleading statements by biotech billionaire Dr. Patrick Soon-Shiong about ...

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the completion of the previously announced change ...